Why the study?
Does sertraline treatment reduce muscle sympathetic nervous activity in patients with moderate-to-severe depression?
Does sertraline treatment reduce muscle sympathetic nervous activity in patients with moderate-to-severe depression?
Sertraline treatment reduces sympathetic overactivity in depressed patients, which may have favorable cardiovascular prognostic implications.
May support CV risk reduction via lower sympathetic activity in depression; leaves open confirmation in RCTs.
Moderate-to-severe depression is associated with increased MSNA. Sertraline treatment reduces MSNA at rest and during mental challenge in depressed patients, which may have prognostic implications in this group.
No takes yet. Share an insight, caveat, or question.
Scalco et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: